BTIG analyst Ryan Zimmerman said while the increase in approvals is promising, longer decision times may have financial implications.
Led by CEO Harry Rowland, VahatiCor is developing the A-Flux coronary sinus reducer implant for coronary microvascular dysfunction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results